Noradrenaline reduces cardiovascular effects of the combined dipyridamole and AMP administration but preserves radioprotective effects of these drugs on hematopoiesis in mice
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8130180
Knihovny.cz E-resources
- MeSH
- Adenosine Monophosphate pharmacology MeSH
- Survival Analysis MeSH
- Whole-Body Irradiation MeSH
- Dipyridamole pharmacology MeSH
- Drug Combinations MeSH
- Hematopoiesis drug effects MeSH
- Cardiovascular System drug effects MeSH
- Oxygen metabolism MeSH
- Mice MeSH
- Norepinephrine pharmacology MeSH
- Radiation-Protective Agents pharmacology MeSH
- Spleen metabolism MeSH
- Body Temperature drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adenosine Monophosphate MeSH
- Dipyridamole MeSH
- Drug Combinations MeSH
- Oxygen MeSH
- Norepinephrine MeSH
- Radiation-Protective Agents MeSH
Recent results of the authors have demonstrated that the elevation of extracellular adenosine induced by the combined administration of dipyridamole, a drug inhibiting the cellular uptake of adenosine, and adenosine monophosphate (AMP), a soluble adenosine prodrug, mediates radioprotective effects in mice. Furthermore, it has been shown that this action is induced by at least two mechanisms: (1) protection by hypoxia as a result of the effects of treatment on the cardiovascular system (bradycardia, vasodilation), and (2) an enhanced regeneration of the radiation-perturbed hematopoiesis. Here, it was ascertained that the joint use of an optimal dose of noradrenaline given with dipyridamole and AMP combination eliminates the hypothermic and hypoxic effects of the treatment, but preserves the radioprotective action of dipyridamole and AMP combination in terms of hematopoietic recovery and partially also survival enhancing effects of the drugs in gamma-irradiated mice. These findings might be of importance for attempts to obtain available and tolerable radioprotective pharmacological prescriptions for clinical use.
The role of adenosine receptor agonists in regulation of hematopoiesis